Early results from clinical trials using ipilimumab after HMA failure show a low overall response rate of 3.4% (21), raising the possibility that the mechanism driving PD-L1 upregulation may matter—a consideration consistent with the fact that PD-L1 expression on antigen-presenting cells is more predictive of response to ICI than PD-L1 on tumor cells (22). Here, CD274 is linked to neoplasm.